January 14, 2008 -- Access Pharmaceuticals (OTCBB: ACCP) has licensed the China marketing rights for its oral mucositis product, MuGard™, to RHEI Pharma, a US-based company that specializes in bringing proprietary medications to China. RHEI says it has 110 national sales reps with access to large volume hospitals in China. But first, RHEI must put the product through the SFDA approval process. Once approved, RHEI will manufacture the product in China and seek to market it throughout Southeast Asia. More details...
